By Lauren Keating
Imagine closing your eyes and feeling as though you've been transported into a room deep within your mind, where memories of the past and dreamlike visions allow you to heal your inner child, confront demons such as addiction and PTSD, and return to reality feeling free—no longer chained to the thoughts and experiences that once fueled an unhealthy mind. The key that unlocked this door was the psychedelic called, Ibogaine.
"Ibogaine is unlike any other psychedelic," said recovery expert Talia Eisenberg. "People sometimes describe a deep life review—revisiting memories, relationships, patterns, and pivotal moments with a level of clarity that can be difficult to access in ordinary consciousness."
This spiritual awakening and healing journey wasn't happening at a party or while experimenting with friends, but rather under the supervision of therapists, addiction specialists, and physicians during medically assisted treatment known as ibogaine therapy.
Eisenberg is the co-founder of Beond, a medically supervised ibogaine treatment clinic based in Cancún, Mexico, that has administered more than 6,000 ibogaine treatments. The goal of ibogaine therapy is to process trauma, break addictive behaviors, and promote lasting mental health improvements. Eisenberg said patients can experience profound insights, forgiveness, self-compassion, or a renewed sense of purpose, as well as revisit painful emotions and traumatic events. While the experience is unique to each individual, ibogaine therapy can be described as your consciousness being able to engage with your subconsciousness.
“What stands out to me is how often people describe seeing their lives with unusual honesty,” she said.
Ibogaine and the Brain
Derived from three West African plants, including the iboga root, ibogaine has been used for centuries among the Bwiti people of Gabon for cultural rituals and religious ceremonies.
The native African tribe does not view it as a drug or medicine, but rather as a tool for connecting to the spiritual realm and facilitating deep self-reflection for healing and awareness.
The iboga root is dried and shaved into chips or ground into a powder and consumed orally by the Bwiti, but in a clinical setting, ibogaine is administered in capsule form.
The altered state of consciousness produced by ibogaine is not merely a psychedelic experience—growing scientific evidence suggests it may offer measurable benefits for brain health and mental well-being. Ibogaine is increasingly being recognized as a potential catalyst for brain repair and psychological healing.
"Ibogaine is a fascinating and unique compound because it does not appear to work through a single mechanism. Instead, it interacts with multiple neurotransmitter systems simultaneously," said neuroscientist
Dr. Shirley Cheung. “Existing research suggests that ibogaine affects serotonin signaling while also influencing broader brain networks involved in reward, mood, motivation, and addictive behavior. They also interact with receptor systems involved in learning and adaptation and may modify the expression of neurotrophic-factor genes in brain regions involved in reward and addiction-related dopaminergic circuits.”
Research has largely been limited to laboratory and animal studies, but brain imaging studies have begun moving claims about brain health benefits from anecdotes toward science. Emerging human studies have shown neurophysiological, functional, and structural changes that are consistent with supporting brain health and neuroplastic processes.
The most compelling human data comes from the Stanford MISTIC study, led by the late Dr. Nolan Williams and colleagues, which included veterans with traumatic brain injury and psychiatric syndromes who received magnesium-ibogaine therapy in Mexico.
“The Stanford group followed their clinical results with EEG and MRI work showing measurable shifts after treatment increased theta-wave activity, which is associated with neuroplasticity,” board-certified physician and PTSD researcher Dr. Eugene Lipov said.
Enhancing neuroplasticity helps the brain form new connections and potentially disrupt unhealthy patterns associated with addiction and trauma. “Seeing the symptom relief mirrored in the imaging is exactly the kind of evidence the field has been waiting for,” Dr. Lipov said.
Separately, a case report in two patients with multiple sclerosis described changes in lesion volume, diffusion imaging markers, and cortical and subcortical brain regions after ibogaine treatment. “These findings are very intriguing because they suggest ibogaine may be associated with measurable changes in brain function or network organization, not just subjective reports of ‘feeling better;” said Dr. Cheung.”
Ibogaine has most notably received attention in treating opioid dependence because of its unusual ability to acutely reduce opioid withdrawal symptoms and cravings in many individuals.
“Ibogaine influences several opioid and non-opioid receptor systems at once, which may help explain why its effects on withdrawal, craving, reward processing, and motivation are so distinct,“ Dr. Cheung,a staff neuroscientist and Head of Research at Beond said.
“Many substance use disorders involve overlapping brain systems related to reward, habit formation, craving, emotional regulation, and compulsive behavior. This is why researchers are also interested in ibogaine’s possible effects across alcohol, stimulants, and polysubstance use, although the strength of evidence varies by substance and remains less developed than the opioid withdrawal literature.”
Beond’s co-founder, Talia Eisenberg, found that ibogaine helped her in her own addiction battle. After struggling with opioids and facing an eating disorder, the psychedelic treatment was able to eliminate drug craving to address the root of her anxiety and shame driving her addictions, so she could change her patterns.
“It’s important to understand that ibogaine doesn’t ‘fix’ you, and it isn’t a magic bullet. It opens what we call the critical period — a window of heightened neuroplasticity in which, with the right environment and support, it becomes much easier to build new habits and let go of the ones that no longer serve,” she said. “What it gave me was a choice where I hadn’t had one before. It lifted the shame that keeps people stuck in the cycle, and it gave me something else: direction.
“There are also active research groups operating under FDA Investigational New Drug authorization studying ibogaine for opioid use disorder, methamphetamine use disorder, and PTSD,” she added.
As interest in psychedelic medicine grows, the United States is moving toward expanded research on therapies once considered taboo. Oregon has legalized supervised psilocybin treatment, Colorado allows limited personal use of certain natural psychedelics, and ketamine is already legally prescribed nationwide for conditions including depression, PTSD, anxiety, bipolar disorder, and migraines. Ibogaine, however, remains a Schedule I substance, prompting many Americans to seek treatment abroad. Momentum for psychedelic research gained further traction in April when President Donald Trump signed an executive order aimed at accelerating FDA review and expanding research into psychedelic therapies. While the FDA's primary focus remains on psilocybin, it has also approved early-stage studies of an ibogaine derivative for alcohol use disorder. Texas has committed $50 million to ibogaine research through clinical trials led by UTHealth Houston and UTMB, while states including Colorado, Arizona, Maryland, New York, Ohio, Kentucky, and Vermont are exploring similar initiatives.
Despite growing enthusiasm, experts emphasize that ibogaine carries significant medical risks and should only be administered in highly controlled clinical settings. "The headline risk is not psychological—it's cardiac," said Dr. Eugene Lipov, noting that ibogaine can prolong the heart's QT interval and potentially trigger life-threatening arrhythmias. Most deaths associated with ibogaine have occurred in unsupervised, unregulated environments. Medical protocols, such as those developed at Stanford, incorporate cardiac-protective measures and continuous monitoring to reduce these risks. Specialized treatment centers conduct extensive screening, including electrocardiograms, laboratory testing, medication reviews, and, when necessary, additional cardiology evaluations. During treatment, clinicians closely monitor heart rhythm, vital signs, oxygen levels, and electrolytes. While some patients describe profound spiritual insights, the experience can also involve intense emotions, vomiting, and prolonged periods of introspection, making ibogaine a powerful but demanding therapy that requires comprehensive medical oversight.
Why Veterans and Researchers Are Paying Attention: New Hope for PTSD
Interest in ibogaine as a potential treatment for post-traumatic stress disorder is growing, particularly among veterans and researchers seeking new approaches for hard-to-treat conditions. A Stanford study involving 30 veterans with traumatic brain injuries who received ibogaine therapy in Mexico reported an 88% reduction in PTSD symptoms and an 87% decrease in depression, with many participants no longer meeting the diagnostic criteria for PTSD and no serious adverse events observed.
Researchers believe ibogaine may help patients revisit traumatic memories in a unique psychological state, allowing them to process emotions, reframe experiences, and reduce the intense fear responses often associated with trauma. According to experts, ibogaine may create a period of heightened neuroplasticity, enabling the brain to form new pathways and move beyond a chronic survival response.
Despite these promising findings, significant challenges remain before ibogaine could become an approved treatment in the United States. Experts emphasize that its cardiac risks require strict medical oversight, including continuous monitoring, specialized clinician training, and administration in certified clinical settings. Additional hurdles include the time, cost, and complexity of large-scale Phase 2 and Phase 3 clinical trials, as well as ongoing debate over whether the psychedelic experience itself is essential to the therapy's effectiveness. Researchers caution that ibogaine is not a standalone cure; long-term recovery depends on comprehensive support, including psychotherapy, social connection, healthy routines, and sustained behavioral change. As momentum builds, advocates believe FDA approval for at least one serious mental health condition is possible, but only through rigorous research, transparent data, and continued investment.
As research into psychedelic-assisted therapies accelerates, ibogaine remains one of the most promising—and closely scrutinized—candidates for treating PTSD, traumatic brain injury, and addiction. While early findings offer hope, experts agree that widespread adoption will depend on rigorous clinical trials, robust safety protocols, and long-term patient support. For veterans and others living with treatment-resistant conditions, ibogaine may represent a new frontier in mental health care—one that requires both scientific innovation and careful medical oversight. Readers interested in learning more can explore information from Beond’s ibogaine treatment program, the Stanford ibogaine study, and the White House executive order on accelerating treatments for serious mental illness.
To Learn More Visit:
Beond: https://beondibogaine.com/about-clinic/
Stanford ibogaine study: https://www.nature.com/articles/s41591-023-02705-w
White House link: https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/
Dr. Shirley Cheung, PhD leads Beond’s research initiatives, transforming clinical outcomes into evidence that advances the field of psychedelic therapy. With a Ph.D. in Neuroscience and Psychology from Lancaster University and prior experience at AstraZeneca, she brings a rigorous, compassionate lens to scientific exploration.
Her work bridges data and impact, helping make healing more accessible and understood.
Talia Eisenberg, MBA is a serial entrepreneur and the co-founder of Beond Co, a San Francisco- and Mexico-based company providing safe and effective psychedelic-assisted ibogaine treatment for those suffering from trauma, addiction, and behavioral disorders. Her passion for supporting others in healing through Ibogaine is personal, as it was the treatment that catalyzed her recovery nearly 15 years ago. It’s what inspired her to open her retreat center in Cancun, where people can come to be safely and comfortably guided through recovery, transformation, and integration.